Breaking News

UPDATE 1-Crucell gets Johnson&Johnson 302 mln euros investment

Sep 28, 2009 02:42AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items

(Corrects headline to euros from $)

* Collaboration to focus on universal flu vaccine

* Crucell share issue equal to 18 percent of share capital

* Deal dilutive to Johnson & Johnson EPS of up to $0.04

(Adds details, company comments)

AMSTERDAM, Sept 28 (Reuters) - Dutch biotechnology firm Crucell said on Monday Johnson & Johnson had bought 14.6 million new Crucell shares for 302 million euros ($443.5 million) as part of a flu vaccine development deal.

Crucell said the collaboration will focus on developing a universal "flu-mAb" product targeting all influenza A strains, including H1N1 strains which cause seasonal flu and the current pandemic flu along with the H5N1 or avian strain.

The newly-issued shares represent about 18 percent of Crucell's outstanding ordinary shares. Both companies also agreed to development milestones and royalty payments based on the successful development and commercialisation of products.

"A universal antibody or vaccine that protects against a broad range of strains would be an important advance in helping ... control acute epidemic and pandemic outbreaks," said Paul Stoffels, global head of pharmaceuticals R&D at Johnson & Johnson.

The collaboration will also focus on development and commercialization of non-flu vaccines for the treatment and prevention of other infectious and non-infectious diseases.

As part of the deal Crucell and Johnson & Johnson affiliate JHC Nederland agreed to a three-year standstill requiring Crucell's consent for an increase of in JHC Nederland's interest in Crucell and a three-month lock-up on transfers of the shares.

The transaction will have an estimated dilutive impact of $0.02 to $0.04 on Johnson & Johnson's 2009 adjusted earnings per share. (Reporting by Aaron Gray-Block; Editing by David Holmes) ($1=.6810 Euro)

UPDATE 1-Crucell gets Johnson&Johnson 302 mln euros investment

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Are you sure you want to delete this chart?
Replace the attached chart with a new chart ?
Post also to:
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Are you sure you want to delete this chart?
Replace the attached chart with a new chart ?
Post 1000
Please wait a minute before you try to comment again.
Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Add Chart to Comment
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
Sign up with Email